This Trial is a Prospective Observational Study of Newly Diagnosed Diffuse Large B Cell Primary Breast Lymphomas

Inclusion Criteria

• •Previously untreated patients with DLBCL of the breast.
• •Patients must have CD20 positive tumors.
• •Stage IE or IIE.
• •Must have at least one objective measurable or evaluable disease. Baseline measurements and evaluations must be obtained within 4 weeks of registration to the study.
• •Patients must have an ECOG performance status 0-2.
• •Patients must have adequate organ function as evidenced by the following laboratory studies ( within 2 weeks prior to registration):
• •* Creatinine Clearance \> 50 ml/min
• •* Total bilirubin \< 2.0 mg/dl and AST \< 2 x upper limit of normal. If documented hepatic involvement with lymphoma, total bilirubin can be \< 3 x ULN, and AST \< 5 x ULN.
• •* Absolute neutrophil count \> 1500/mm3 and platelet count \> 100,000/mm3. If documented bone marrow involvement with lymphoma, absolute neutrophil count \> 500/mm3 and platelet count \> 50,000/mm3.
• •Patients must be age \> 18 years.
• •Patients must have a normal left ventricular ejection fraction to be eligible.